LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance

Q1 revenue of $2.79 billion , down 2% from $2.85 billion last year Q1 diluted EPS of $1.86 , up 11% from $1.67 last year; Q1 adjusted EPS of $2.62 , down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45 , from $11.00 to $11.40 2019 free cash flow guidance of $950

LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider

LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United

LabCorp to Announce First Quarter Financial Results on April 30, 2019

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality for Second Year in a Row BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect